Post-Transplant Hypertension in Kidney Recipients: Current Knowledge, Gaps and Future Directions.

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Cardiovascular disease is the primary cause of death in kidney transplant recipients (KTRs).
• Arterial hypertension is the most common cardiovascular comorbidity post-transplantation, significantly increasing risks.
• Existing guidelines lack specific blood pressure control strategies for KTRs, relying on extrapolated data.

Purpose of the Study:

• To highlight the evidence gap in managing post-transplant hypertension.
• To emphasize the need for updated guidelines and research in KTRs.
• To discuss potential impacts of immunosuppressive therapy on blood pressure control.

Main Methods:

• Review of current literature and clinical guidelines.
• Analysis of existing data on antihypertensive medication effectiveness in KTRs.
• Exploration of immunosuppressive therapy's role in blood pressure management.

Main Results:

• Current antihypertensive treatment guidelines for KTRs are based on limited, outdated data.
• First-line medications like calcium channel blockers and ARBs have efficacy data over 15 years old.
• Immunosuppressive therapy modification (e.g., reducing calcineurin inhibitors or steroids) may improve blood pressure.

Conclusions:

• There is a critical need for large, contemporary randomized trials in KTRs.
• Optimizing immunosuppression is a potential strategy for better blood pressure control.
• Updated evidence-based guidelines are essential for effective post-transplant hypertension management.